T-cell engaging–therapies have transformed the treatment landscape of relapsed and
refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients …

Clinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown
high overall response rates in patients with relapsed/refractory B-cell malignancies. CART19 …

PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …

Checkpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas …

Background Outcomes are poor for patients with large B-cell lymphoma who relapse after
CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly …

COI notes: SAG: Advisory Board for Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz
pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma; Research funding from Amgen …

Current standard-of-care for relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) comprises chemotherapy and autologous stem cell transplantation (ASCT). 1 …

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre-or post-anti-CD19
chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large …

Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T)
therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity …

This study retrospectively evaluated the outcome of salvage therapy in 51 patients who
failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B‐cell …